Health Care Sector Update for 12/15/2015: ARQL, NLNK, SAGE
Top Health-care stocks:
Health-care shares were mainly unchanged in pre-market trade on Tuesday.
In health-care stocks news, ArQule ( ARQL ), a biopharmaceutical company, said it has received orphan drug designation from the Food and Drug Administration for ARQ 087 in the treatment of cholangiocarcinoma, or CCA.
Shares in the company were unchanged at $2.11 pre-bell. This is within the upper band of the stock's 52 week trading range between $1.05 and $2.65.
NewLink Genetics ( NLNK ), a biopharmaceutical company, said Tuesday that it has completed enrollment in the Phase 3 PILLAR (Pancreatic Immunotherapy with algenpantucel-L for Locally Advanced non-Resectable cancer) clinical trial of algenpantucel-L for patients with borderline resectable or locally advanced unresectable pancreatic cancer.
Shares in the company were also unchanged at $32.73. This is within the lower band of the stock's 52 week trading range between $31.56 and $58.73.
And Sage Therapeutics ( SAGE ) Thursday reported it expected a readout of top-line results for its phase 3 trial of its drug SAGE-547, a treatment for patients with super-refractory status epilepticus (SRSE), in H2 2016.
Shares were flat at $51.40 pre-bell. This is within the lower band of the stock's 52 week trading range between $34.14 and $89.04.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.